AAAAAA

   
Results: 1-15 |
Results: 15

Authors: Propper, DJ McDonald, AC Man, A Thavasu, P Balkwill, F Braybrooke, JP Caponigro, F Graf, P Dutreix, C Blackie, R Kaye, SB Ganesan, TS Talbot, DC Harris, AL Twelves, C
Citation: Dj. Propper et al., Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C, J CL ONCOL, 19(5), 2001, pp. 1485-1492

Authors: Katso, RMT Manek, S Ganjavi, H Biddolph, S Charnock, MFL Bradburn, M Wells, M Ganesan, TS
Citation: Rmt. Katso et al., Overexpression of H-Ryk in epithelial ovarian cancer: Prognostic significance of receptor expression, CLIN CANC R, 6(8), 2000, pp. 3271-3281

Authors: Braybrooke, JP O'Byrne, KJ Propper, DJ Blann, A Saunders, M Dobbs, N Han, C Woodhull, J Mitchell, K Crew, J Smith, K Stephens, R Ganesan, TS Talbot, DC Harris, AL
Citation: Jp. Braybrooke et al., A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis, CLIN CANC R, 6(12), 2000, pp. 4697-4704

Authors: Braybrooke, JP Vallis, KA Houlbrook, S Rockett, H Ellmen, J Anttila, M Ganesan, TS Harris, AL Talbot, DC
Citation: Jp. Braybrooke et al., Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine, CANC CHEMOT, 46(1), 2000, pp. 27-34

Authors: Odunsi, KO van Ee, CC Ganesan, TS Shelling, AN
Citation: Ko. Odunsi et al., Evaluation of the possible protective role of adeno-associated virus type 2 infection in HPV-associated premalignant disease of the cervix, GYNECOL ONC, 78(3), 2000, pp. 342-345

Authors: Braybrooke, JP Propper, DJ O'Byrne, KJ Koukourakis, MI Patterson, AV Houlbrook, S Love, SD Varcoe, S Taylor, M Ganesan, TS Talbot, DC Harris, AL
Citation: Jp. Braybrooke et al., Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid andinterferon alpha, BR J CANC, 83(2), 2000, pp. 219-224

Authors: Propper, DJ Braybrooke, JP Levitt, NC O'Byrne, KO Christodoulos, K Han, C Talbot, DC Ganesan, TS Harris, AL
Citation: Dj. Propper et al., Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine, BR J CANC, 82(11), 2000, pp. 1759-1763

Authors: Propper, DJ Levitt, NC O'Byrne, K Braybrooke, JP Talbot, DC Ganesan, TS Thompson, CH Rajagopalan, B Littlewood, TJ Dixon, RM Harris, AL
Citation: Dj. Propper et al., Phase II study of the oxygen saturation curve left shifting agent BW12C incombination with the hypoxia activated drug mitomycin C in advanced colorectal cancer, BR J CANC, 82(11), 2000, pp. 1776-1782

Authors: Propper, DJ Saunders, MP Salisbury, AJ Long, L O'Byrne, KJ Braybrooke, JP Dowsett, M Taylor, M Talbot, DC Ganesan, TS Harris, AL
Citation: Dj. Propper et al., Phase I study of the novel cyclic AMP (cAMP) analogue 8-chloro-cAMP in patients with cancer: Toxicity, hormonal, and immunological effects, CLIN CANC R, 5(7), 1999, pp. 1682-1689

Authors: Propper, DJ Braybrooke, JP Taylor, DJ Lodi, R Styles, P Cramer, JA Collins, WCJ Levitt, NC Talbot, DC Ganesan, TS Harris, AL
Citation: Dj. Propper et al., Phase I trial of the selective mitochondrial toxin MKT 077 in chemo-resistant solid tumours, ANN ONCOL, 10(8), 1999, pp. 923-927

Authors: O'Byrne, KJ Philip, PA Propper, DJ Braybrooke, JP Saunders, MP Bates, NP Taylor, MA Madigan, D Ganesan, TS Talbot, DC Harris, AL
Citation: Kj. O'Byrne et al., A phase II study of the modulation of 5-fluorouracil and folinic acid withhigh-dose infusional hydroxyurea in metastatic colorectal carcinoma, ANN ONCOL, 10(8), 1999, pp. 981-983

Authors: Katso, RM Russell, RB Ganesan, TS
Citation: Rm. Katso et al., Functional analysis of H-Ryk, an atypical member of the receptor tyrosine kinase family, MOL CELL B, 19(9), 1999, pp. 6427-6440

Authors: Katso, RMT Manek, S Biddolph, S Whittaker, R Charnock, MFL Wells, M Ganesan, TS
Citation: Rmt. Katso et al., Overexpression of H-Ryk in mouse fibroblasts confers transforming ability in vitro and in vivo: Correlation with up-regulation in epithelial ovarian cancer, CANCER RES, 59(10), 1999, pp. 2265-2270

Authors: O'Byrne, KJ Koukourakis, MI Saunders, MP Salisbury, AJ Isaacs, R Varcoe, S Taylor, M Ganesan, TS Harris, AL Talbot, DC
Citation: Kj. O'Byrne et al., Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer, BR J CANC, 77(11), 1998, pp. 1950-1956

Authors: Macaulay, VM O'Byrne, KJ Green, JA Philip, PA McKinley, L LaCreta, FP Winograd, B Ganesan, TS Harris, AL Talbot, DC
Citation: Vm. Macaulay et al., Phase I study of the mitomycin C analogue BMS-181174, BR J CANC, 77(11), 1998, pp. 2020-2027
Risultati: 1-15 |